Acceptability of Microarray Patches for Delivery of HIV Pre-exposure Prophylaxis (PrEP) Among Women and Health Care Providers in South Africa

As part of PATH’s work in vaccine and pharmaceutical delivery technologies, this poster presents results from a user-acceptability study of two microarray patches (MAPs) in South Africa. The MAPs under assessment were designed for the self-administration of antiretrovirals, such as rilpilvirine, and may someday offer a discreet and effective form of PrEP protection for women at risk of HIV.

Publication date: May 2016

Acceptability of Microarray Patches for Delivery of HIV Pre-exposure Prophylaxis (PrEP) Among Women and Health Care Providers in South Africa

1.5 MB PDF

Hard copies are not available.

View Resource